It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
As a substrate and major effector of the mammalian target of rapamycin complex 1 (mTORC1), the biological functions of ribosomal protein S6 kinase (S6K) have been canonically assigned for cell size control by facilitating mRNA transcription, splicing, and protein synthesis. However, accumulating evidence implies that diverse stimuli and upstream regulators modulate S6K kinase activity, leading to the activation of a plethora of downstream substrates for distinct pathobiological functions. Beyond controlling cell size, S6K simultaneously plays crucial roles in directing cell apoptosis, metabolism, and feedback regulation of its upstream signals. Thus, we comprehensively summarize the emerging upstream regulators, downstream substrates, mouse models, clinical relevance, and candidate inhibitors for S6K and shed light on S6K as a potential therapeutic target for cancers.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Sun Yat-sen University, Department of Liver Surgery, Hepatobiliary Pancreatic Center, the First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X); Sun Yat-sen University, Institute of Precision Medicine, the First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X)
2 Sun Yat-sen University, Institute of Precision Medicine, the First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X)
3 Sun Yat-sen University, Department of Liver Surgery, Hepatobiliary Pancreatic Center, the First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X)
4 Harvard Medical School, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)